RO 5095932

Drug Profile

RO 5095932

Alternative Names: RO-5095932

Latest Information Update: 07 Aug 2013

Price : $50

At a glance

  • Originator Roche
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Aug 2013 No development reported - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 31 Aug 2011 Roche completes a Phase-I trial in Type 2 diabetes mellitus in USA (NCT00961909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top